- Home
- TNGX vs APLE Comparison
TNGX vs APLE Comparison
Compare TNGX & APLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | APLE |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TNGX | APLE |
|---|---|---|
| Price | $26.50 | $13.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $20.00 | $13.00 |
| AVG Volume (30 Days) | 2.8M | ★ 3.7M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 7.38% |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ 0.74 |
| Revenue | $62,384,000.00 | ★ $1,238,622,000.00 |
| Revenue This Year | N/A | $2.59 |
| Revenue Next Year | N/A | $2.42 |
| P/E Ratio | ★ N/A | $17.57 |
| Revenue Growth | ★ 48.29 | 18.98 |
| 52 Week Low | $1.04 | $10.85 |
| 52 Week High | $26.81 | $13.27 |
Technical Indicators
Market Signals| Indicator | TNGX | APLE |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 74.16 |
| Support Level | $6.54 | $11.48 |
| Resistance Level | N/A | $13.27 |
| Average True Range (ATR) | 1.46 | 0.27 |
| MACD | 0.44 | 0.14 |
| Stochastic Oscillator | 91.67 | 98.89 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About APLE Apple Hospitality REIT Inc.
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.